Dr. Barlow will take up the role on or before 1 May 2017, at which point he will be appointed to the e-Therapeutics Board of Directors.
Dr. Barlow, aged 48, is currently Executive Director of Corporate Development at Amgen Inc. based in Switzerland.
He brings to e-Therapeutics broad experience of drug discovery, development and commercialisation, acquired through regional and global roles in the biotech and pharmaceutical sector.
His previous responsibilities have included scientific, business and corporate roles with Astra Zeneca, Crucell and Johnson and Johnson.
e-Therapeutics’ Chairman, Mr. Iain Ross said:“On behalf of the team, I welcome Ray to e-Therapeutics. He joins the Company at an exciting time and is a consummate business professional who brings a wealth of relevant experience from the international pharmaceutical and biotech sector. I am confident that, as CEO, he will lead us through the next stage of the Company’s development and achieve both our short and long term goals. I would also like to take this opportunity to thank the e-Therapeutics team for the tremendous effort they have made over the last six months whilst the business has been in transition and has refocused its strategy.”
Ray Barlow added, “As our understanding of human disease and genetics deepens, it is clear that that the traditional “reductionist” approach to drug discovery is only potentially part of the solution. I believe that e-Therapeutics’ computational-based, network biology approach provides a valuable, productive and differentiated means to create novel medicines to treat inherently complex diseases. Once I’m on board, my aim is to continue building the network pharmacology platform, generating additional supporting data for the internal programmes, and on communicating to the industry the utility of this approach in addressing some of the biggest challenges it faces in treating serious and debilitating diseases. I am looking forward to working with the e-Therapeutics’ team and driving the Company forward to reach its full potential.”
